Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 4/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 7/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949275 | 1.00 | GPR183 (0.51) | GPR183NFKB1MAOBTRPM8P4HB | |
| SCHEMBL1950810 | 0.83 | GPR183 (0.50) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1950814 | 0.83 | GPR183 (0.50) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1953456 | 0.81 | GPR183 (0.49) | GPR183NFKB1MAOBTRPM8P4HB | |
| SCHEMBL12548156 | 0.80 | GPR183 (0.48) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1952170 | 0.80 | GPR183 (0.48) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1953422 | 0.79 | MAPT (0.47) | GPR183MAPTL3MBTL1RAB9A | |
| SCHEMBL1953427 | 0.79 | MAPT (0.47) | GPR183MAPTL3MBTL1RAB9A | |
| SCHEMBL1952309 | 0.77 | HSD11B1 (0.53) | GPR183NFKB1MAOBKEAP1NFE2L2 | |
| SCHEMBL1952348 | 0.77 | HSD11B1 (0.53) | GPR183NFKB1MAOBKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265588-B1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | VITAE PHARMACEUTICALS INC. | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | GPR183 1523/4885NFKB1 1003/4885MAOB 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.